Results 1 to 10 of about 142,695 (370)
Clinical and Translational Science, 2023 This analysis was conducted to inform dose selection of a combination of nivolumab plus ipilimumab for the treatment of sorafenib‐experienced patients with hepatocellular carcinoma (HCC).
Bruno Sangro +9 more
doaj +1 more source
Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study. [PDF]
PLoS ONE, 2018 OBJECTIVES:The effectiveness of treatment after cessation of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) has not been well investigated.
Yukihiro Yano +12 more
doaj +1 more source
Severe lichenoid eruption due to concomitant medications following nivolumab administration
JEADV Clinical Practice, 2023 Recently, immune checkpoint inhibitors have been administered for several cancers and have shown great efficacy. However, they are associated with various immune‐related adverse events.
Risa Kakuta +7 more
doaj +1 more source
The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England [PDF]
, 2018 Background: Nivolumab was the first programmed death receptor 1 (PD-1) immune checkpoint inhibitor to demonstrate long-term survival benefit in a clinical trial setting for advanced melanoma patients.
Ellis, John +8 more
core +1 more source
ERJ Open Research, 2018 Nivolumab for the treatment of advanced nonsmall cell lung cancer (NSCLC) evaluated in phase III trials showed 50% progression at first evaluation, but better overall survival (OS), suggesting regained efficacy of treatments given thereafter. We aimed to
Adrien Costantini +14 more
doaj +1 more source
Immune checkpoint inhibitors in renal cell carcinoma [PDF]
, 2017 The immune system has long been known to play a critical role in the body's defence against cancer, and there have been multiple attempts to harness it for therapeutic gain.
Jones, Robert J., Ross, Kirsty
core +1 more source
Nivolumab‐induced acute tubular injury: A case report
Clinical Case Reports, 2023 Nivolumab belongs to immune checkpoint inhibitors (ICIs). ICIs‐induced kidney injury is rare and acute interstitial nephritis (AIN) is the majority. A 58‐year‐old woman had gastric cancer treated with nivolumab.
Hui‐Hsin Yang +2 more
doaj +1 more source
The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC [PDF]
, 2017 Background: Immune checkpoint inhibitors improve outcomes compared with chemotherapy in lung cancer. Tumor PD-L1 receptor expression is being studied as a predictive biomarker. The objective of this study was to assess the cost-effectiveness and economic
Abdel-Rahman +25 more
core +3 more sources
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]
, 2015 Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core +2 more sources
IJU Case Reports, 2021 Introduction The efficacy of nivolumab for non‐clear cell renal cell carcinoma is still unclear. We present a rare case of metastatic papillary renal cell carcinoma remarkably responded to nivolumab but developed myeloradiculoneuropathy as immune‐related
Kazunori Iwasaki +6 more
doaj +1 more source